X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/pharma/less-year-after-biogen-buyout-reatas-would-be-rare-disease-blockbuster-passes-muster-eu
https://www.globenewswire.com/news-release/2023/12/15/2797103/0/en/CHMP-Issues-Positive-Opinion-for-Biogen-s-SKYCLARYS-omaveloxolone-the-First-Therapy-to-Treat-Friedreich-s-Ataxia-a-Rare-Neurodegenerative-Disease.html
https://health.economictimes.indiatimes.com/news/pharma/biogen-to-buy-reata-for-6-5-bln-to-bulk-up-rare-disease-portfolio/102220586
https://www.globenewswire.com/news-release/2023/07/28/2713028/0/en/Biogen-to-Acquire-Reata-Pharmaceuticals.html
https://www.dallasnews.com/business/health-care/2023/06/28/plano-based-reata-pharmaceuticals-launches-its-first-drug-skyclarys/
https://www.fiercepharma.com/pharma/reata-scores-first-fda-approval-its-21-year-history-pushing-rare-disease-drug-over-finish
https://www.fiercebiotech.com/biotech/after-addressing-fdas-concerns-reuta-has-wait-ataxia-drug-decision-delayed-3-months
https://endpts.com/karunas-schizophrenia-drug-passes-a-closely-watched-phii-test-will-head-to-fda-in-mid-2023/
https://www.globenewswire.com/news-release/2020/11/24/2133233/0/en/Reata-Provides-Update-on-Omaveloxolone-Program-for-Patients-with-Friedreich-s-Ataxia.html#:~:text=Reata%20Provides%20Update%20on%20Omaveloxolone%20Program%20for%20Patients%20with%20Friedreich's%20Ataxia,-Email%20Print%20Friendly&text=November%2024%2C%202020%2017%3A00,Source%3A%20Reata%20Pharmaceuticals%2C%20Inc.&text=%E2%80%9COmaveloxolone%20improved%20motor%20function%20as,and%20the%20Baseline%2DControlled%20study.
https://endpts.com/reata-suggests-friedreichs-ataxia-program-could-be-delayed-sending-stock-plunging/
https://www.fiercebiotech.com/biotech/reata-shocks-analysts-pivotal-win-friedreich-s-ataxia
https://seekingalpha.com/news/3505622-reatas-omaveloxolone-successful-mid-stage-fa-study
https://reatapharma.gcs-web.com/news-releases/news-release-details/reata-receives-orphan-drug-designation-european-commission
https://globenewswire.com/news-release/2018/07/27/1543439/0/en/Reata-Pharmaceuticals-Inc-Announces-Closing-of-Class-A-Common-Stock-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html
https://reatapharma.gcs-web.com/news-releases/news-release-details/reata-announces-new-preclinical-data-demonstrating-potential
Market Place
Share 
